Literature DB >> 21621553

Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death.

Monika C Wolkers1, Steven J Bensinger, Douglas R Green, Stephen P Schoenberger, Edith M Janssen.   

Abstract

CD8(+) T cells primed in the absence of CD4(+) T cell help are programmed to produce TRAIL, which results in Death receptor (DR5) mediated apoptosis upon restimulation. Here, we studied whether these 'helpless' effector CD8(+) T cells are consigned to an apoptotic fate or whether their helpless program can be altered by inflammatory or growth cytokines. We found that helpless CD8(+) T cells regained their full proliferative and functional capacity only when IL-2 was added to cell cultures, while IL-7 and IL-15, two common gamma chain cytokines associated with CD8(+) T cell homeostasis and memory, could only partly restore secondary expansion in helpless CD8(+) T cells. Recovery of functional CD8(+) T cell immunity by IL-2 was concomitant with induction of IL2Rα (CD25) expression, downregulation of TRAIL, and the upregulation of anti-apoptotic molecules Bcl-2 and FLIP. The addition of IL-2 to helpless CD8(+) T cells also interfered with DR5-mediated apoptosis induction, indicating that IL-2 affects several components of the TRAIL-DR5 pathway. Collectively, these data demonstrate that the helpless phenotype is not fixed, and that IL-2R signaling at the time of reactivation can play an important role in restoring CD8(+) T cell function.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621553      PMCID: PMC3146632          DOI: 10.1016/j.imlet.2011.04.011

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  31 in total

1.  The numbers game for virus-specific CD8+ T cells.

Authors:  P C Doherty
Journal:  Science       Date:  1998-04-10       Impact factor: 47.728

Review 2.  T cell memory.

Authors:  R W Dutton; L M Bradley; S L Swain
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

3.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.

Authors:  K Murali-Krishna; J D Altman; M Suresh; D J Sourdive; A J Zajac; J D Miller; J Slansky; R Ahmed
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

4.  Massive expansion of antigen-specific CD8+ T cells during an acute virus infection.

Authors:  E A Butz; M J Bevan
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

5.  CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

Authors:  Edith M Janssen; Nathalie M Droin; Edward E Lemmens; Michael J Pinkoski; Steven J Bensinger; Benjamin D Ehst; Thomas S Griffith; Douglas R Green; Stephen P Schoenberger
Journal:  Nature       Date:  2005-03-03       Impact factor: 49.962

Review 6.  cFLIP regulation of lymphocyte activation and development.

Authors:  Ralph C Budd; Wen-Chen Yeh; Jürg Tschopp
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

7.  Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells.

Authors:  S P Schoenberger; E I van der Voort; G M Krietemeijer; R Offringa; C J Melief; R E Toes
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

8.  Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.

Authors:  M F Callan; L Tan; N Annels; G S Ogg; J D Wilson; C A O'Callaghan; N Steven; A J McMichael; A B Rickinson
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

9.  Defective CD8 T cell memory following acute infection without CD4 T cell help.

Authors:  Joseph C Sun; Michael J Bevan
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

10.  Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

Authors:  Kazuyoshi Takeda; Noriko Yamaguchi; Hisaya Akiba; Yuko Kojima; Yoshihiro Hayakawa; Jane E Tanner; Thomas J Sayers; Naoko Seki; Ko Okumura; Hideo Yagita; Mark J Smyth
Journal:  J Exp Med       Date:  2004-02-09       Impact factor: 14.307

View more
  8 in total

1.  Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression.

Authors:  Monika C Wolkers; Carmen Gerlach; Ramon Arens; Edith M Janssen; Patrick Fitzgerald; Ton N Schumacher; Jan Paul Medema; Douglas R Green; Stephen P Schoenberger
Journal:  Blood       Date:  2011-11-29       Impact factor: 22.113

2.  The CD4⁺ T-cell help signal is transmitted from APC to CD8⁺ T-cells via CD27-CD70 interactions.

Authors:  Sonia Feau; Zacarias Garcia; Ramon Arens; Hideo Yagita; Jannie Borst; Stephen P Schoenberger
Journal:  Nat Commun       Date:  2012-07-10       Impact factor: 14.919

3.  Relationship between XspI Site Polymorphisms of LDL-R Gene and Serum IL-2 and IL-10 in Patients with Hypercholesterolemia.

Authors:  Mingming Zhang; Yamin Lu; Xin Liu; Xiaobin Zhang; Cuigai Zhang; Wei Gao; Yanqing Tie
Journal:  J Clin Lab Anal       Date:  2016-04-28       Impact factor: 2.352

4.  Epitope-specific regulation of memory programming by differential duration of antigen presentation to influenza-specific CD8(+) T cells.

Authors:  André Ballesteros-Tato; Beatriz León; Byung O Lee; Frances E Lund; Troy D Randall
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745

Review 5.  Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Authors:  Gustavo P Amarante-Mendes; Thomas S Griffith
Journal:  Pharmacol Ther       Date:  2015-09-05       Impact factor: 12.310

Review 6.  T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression.

Authors:  Stephanie A Condotta; Javier Cabrera-Perez; Vladimir P Badovinac; Thomas S Griffith
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 7.  Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act.

Authors:  Vandana Kalia; Surojit Sarkar
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

Review 8.  The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses.

Authors:  Duygu Sag; Zeynep Ozge Ayyildiz; Sinem Gunalp; Gerhard Wingender
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.